Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

Reck, MCiuleanu, T-ECobo, MSchenker, MZurawski, BMenezes, JRichardet, EBennouna, JFelip, EJuan-Vidal, OAlexandru, ASakai, HLingua, AReyes, FSouquet, P-JDe Marchi, PMartin, CPérol, MScherpereel, ALu, SPaz-Ares, LCarbone, D PMemaj, AMarimuthu, SZhang, XTran, PJohn, T2025-01-072025-01-072021-12-02https://hdl.handle.net/10668/24575enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].research article34864501open access10.1016/j.esmoop.2021.1003452059-7029PMC8649668https://doi.org/10.1016/j.esmoop.2021.100345https://pmc.ncbi.nlm.nih.gov/articles/PMC8649668/pdf